Boston Scientific beats second quarter expectations, raises full-year outlook

Boston Scientific Corp ( NYSE:BSX XETRA:BSX ) View Price & Profile Boston Scientific beats second quarter expectations, raises full-year outlook Published: 12:07 29 Jul 2026 EDT Boston Scientific Corp (NYSE:BSX, XETRA:BSX) reported second quarter results that exceeded analyst expectations for revenue and adjusted earnings, while raising its full-year sales outlook. The medical device company posted adjusted earnings per share of $0.86, ahead of the $0.83 consensus estimate, while revenue reached $5.442 billion, compared with analyst expectations of $5.37 billion. Revenue increased 7.5% on a reported basis and 7.0% on an operational and organic basis compared with the prior-year period. Boston Scientific reported GAAP net income attributable to common stockholders of $907 million, or $0.61 per share, compared with $797 million, or $0.53 per share, in the same period a year earlier. Adjusted EPS rose to $0.86 from $0.75 in the second quarter of 2025. "Our team delivered a solid quarter while continuing to navigate a dynamic environment," Boston Scientific CEO Mike Mahoney said in a statement. "We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities, and we remain confident in Boston Scientific's long-term growth, anchored by our category leadership strategy and our commitment to meaningful innovation for patients and physicians." The company’s Cardiovascular segment recorded the strongest growth among its two major businesses, with sales increasing 8.3% on a reported basis and 7.8% on an operational and organic basis. The MedSurg segment reported sales growth of 5.9% on a reported basis and 5.4% on an operational and organic basis. By geography, US sales increased 6.2% on both a reported and operational basis. Sales in Europe, the Middle East and Africa ...